Illumina, Inc. $ILMN Stock Sold by Insight Wealth Strategies LLC

Key Points

• Insight Wealth Strategies cut its Illumina stake by 25.7% in the third quarter, selling 8,479 shares and retaining 24,488 shares worth approximately $6.7 million.
• Institutional investors own 89.42% of Illumina, while insiders sold more than 2 million shares worth $436.5 million over the past 90 days.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $222.19 price target, despite Illumina exceeding quarterly earnings and revenue estimates and reporting 9.4% year-over-year revenue growth.

Insight Wealth Strategies LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 25.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,488 shares of the life sciences company's stock after selling 8,479 shares during the quarter. Insight Wealth Strategies LLC's holdings in Illumina were worth $6,702,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ILMN. BlackRock Inc. bought a new stake in Illumina during the 2nd quarter valued at $3,374,423,000. WCM Investment Management LLC lifted its stake in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA purchased a new stake in shares of Illumina during the 2nd quarter worth $617,981,000. Jupiter Topco LLC bought a new stake in Illumina during the second quarter valued at about $358,652,000. Finally, Wellington Management Group LLP boosted its position in Illumina by 190.1% during the second quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company's stock valued at $318,767,000 after purchasing an additional 1,188,004 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 2,061,850 shares of company stock valued at $436,479,102. Company insiders own 2.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on ILMN shares. Royal Bank Of Canada increased their price target on shares of Illumina from $230.00 to $310.00 and gave the company an "outperform" rating in a research report on Monday. Citigroup boosted their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a "sell" rating in a research note on Monday, August 3rd. Argus increased their target price on shares of Illumina from $180.00 to $235.00 and gave the company a "buy" rating in a research report on Thursday, September 3rd. UBS Group upgraded shares of Illumina from a "neutral" rating to a "buy" rating and raised their target price for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Finally, Deutsche Bank Aktiengesellschaft downgraded Illumina to a "hold" rating in a research report on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Illumina has an average rating of "Hold" and a consensus price target of $222.19.

Illumina Stock Performance

Shares of Illumina stock traded up $7.76 during midday trading on Friday, hitting $272.33. The company had a trading volume of 729,119 shares, compared to its average volume of 2,169,474. The company has a fifty day simple moving average of $225.72 and a 200 day simple moving average of $180.21. The stock has a market cap of $41.12 billion, a price-to-earnings ratio of 50.77, a PEG ratio of 3.79 and a beta of 1.41. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $309.35.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.